Description du projet
Protéger la peau des patients stomisés
Chaque année, des milliers de personnes font l’objet d’une stomie. Les complications cutanées sont fréquentes chez les patients stomisés. En effet, 40 % des patients urostomisés et iléostomisés sont atteints de complications cutanées. L’entreprise Ostoform de l’Université de Limerick a une expérience unique dans l’utilisation de technologies brevetées pour améliorer la santé cutanée des patients stomisés. Ostoform Seal est un produit combinant l’utilisation de matériaux absorbants et non absorbants pour empêcher le contact entre les acides et la peau. Ce produit réduit les coûts, car il diminue la fréquence de changements des poches de stomie et de visites à la clinique. Des tests ont révélé une réduction de 45 % des complications cutanées. Le projet OSTOFORM, financé par l’UE, créera une ligne industrielle complète pour commercialiser ce produit.
Objectif
Ostoform is a spin-out medical device company from the University of Limerick, Ireland with a range of patented technologies, and the potential to scale, becoming a global leader in the area of ostomy skin health. There is enormous opportunity to address needs in the ostomy market, with 40% of all ileostomy and urostomy patients suffering from skin complications. The Ostoform Seal- the company’s first, award-winning product- uses a unique, patented combination of absorbent and non-absorbent materials to prevent acidic output from contacting the patient’s skin. Patient benefits of this product include healthier skin, better usability, increased patient confidence and improved patient quality of life. The devicecan also reduce costs for healthcare systems by reducing visits to ostomy nurses and by reducing the frequency with whichpatients change their ostomy bags.
The addressable patient population for the Ostoform Seal is approximately 1,000,000 in the EU and US combined, resulting in an annual market of $725m.
The device is a Class I medical device with a clear regulatory pathway and pre-existing reimbursement in the US. A 45% improvement in skin condition has already been demonstrated in a six-week study involving 12 patients. Following completion of the SME Instrument Phase I, Ostoform has secured €1.1m in private investment. This capital, along with SME Instrument Phase 2 funding will support further patient trials, which in turn will improve reimbursement pricing for the device. A full manufacturing line will also be established, with the company being fully market ready by December 2020.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
SME-2 - SME instrument phase 2Coordinateur
N91 W5NN Mullingar Co Westmeath
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.